hydroxychloroquine has been researched along with Neurovisceral Storage Disease with Vertical Supranuclear Ophthalmoplegia in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballout, RA | 1 |
| Sviridov, D | 1 |
| Bukrinsky, MI | 1 |
| Remaley, AT | 1 |
| Sturley, SL | 1 |
| Rajakumar, T | 1 |
| Hammond, N | 1 |
| Higaki, K | 1 |
| Márka, Z | 1 |
| Márka, S | 1 |
| Munkacsi, AB | 1 |
1 review available for hydroxychloroquine and Neurovisceral Storage Disease with Vertical Supranuclear Ophthalmoplegia
| Article | Year |
|---|---|
Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity.
Topics: Androstenes; Angiotensin-Converting Enzyme 2; Anticholesteremic Agents; Antiviral Agents; Betacorona | 2020 |
1 other study available for hydroxychloroquine and Neurovisceral Storage Disease with Vertical Supranuclear Ophthalmoplegia
| Article | Year |
|---|---|
The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.
Topics: ADAM17 Protein; Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; | 2020 |